Shares of Cortex Pharmaceuticals Inc. plunged 59 percent after the FDA rejected a proposal for a Phase IIb trial of lead ampakine compound CX717 in attention deficit hyperactivity disorder. (BioWorld Today)

Shares of Cortex Pharmaceuticals Inc. plunged 59 percent after the FDA rejected a proposal for a Phase IIb trial of lead ampakine compound CX717 in attention deficit hyperactivity disorder. (BioWorld Today)

While waiting to price its initial public offering, Anacor Pharmaceuticals Inc. signed a deal with GlaxoSmithKline plc for the discovery, development and commercialization of small-molecule, boron-based antivirals and antibacterials. (BioWorld Today)

While waiting to price its initial public offering, Anacor Pharmaceuticals Inc. signed a deal with GlaxoSmithKline plc for the discovery, development and commercialization of small-molecule, boron-based antivirals and antibacterials. (BioWorld Today)